【过敏性鼻炎治疗研究取得新进展】金十数据4月5日讯，首都医科大学附属北京同仁医院张罗教授团队在国际医学期刊《自然·医学》发表最新研究成果。该研究发现，新型生物制剂司普奇拜单抗可显著改善中重度季节性过敏性鼻炎患者的临床症状及生活质量。基于临床需求，张罗教授团队开展了名为“天玑”的多中心、随机、双盲、安慰剂对照的Ⅲ期临床试验，在全国18个研究中心纳入108例中重度季节性过敏性鼻炎患者，以证实新型生物制剂司普奇拜单抗的临床疗效。Ⅲ期临床试验研究结果显示，司普奇拜单抗能有效改善患者的鼻部和眼部症状。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.